1502TiP Paclitaxel + ramucirumab versus paclitaxel alone in patients with squamous-cell carcinoma of the esophagus, refractory or intolerant to combination therapy with fluoropyrimidine and platinum-based drugs - RAMOS, a randomized phase II trial of the German Gastric Group of the AIO

S Lorenzen,S Junge,A Treschl,R.D Hofheinz,S-E Al-Batran,G Frost,C Pauligk,S Heidel,T.O Götze,H Schmalenberg,C Michael,R.J.C Mahlberg,M Moehler,A Biederstädt

doi:10.1016/j.annonc.2020.08.2093

1502TiP Paclitaxel + ramucirumab versus paclitaxel alone in patients with squamous-cell carcinoma of the esophagus, refractory or intolerant to combination therapy with fluoropyrimidine and platinum-based drugs - RAMOS, a randomized phase II trial of the German Gastric Group of the AIO

S Lorenzen, S Junge + Show 12 more

Open Access

https://doi.org/10.1016/j.annonc.2020.08.2093

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2020
Citations: 1	License type: publisher-specific-oa

Affiliation: Technical University of Munich, Krankenhaus Nordwest, Städtisches Klinikum Dresden, Klinikum Saarbrücken, Klinikum Mutterhaus der Borromäerinnen

#Squamous-cell Carcinoma Of The Esophagus #Platinum-based Drugs + Show 2 more

Abstract
Full-Text PDF
Similar Papers

Abstract

1502TiP Paclitaxel + ramucirumab versus paclitaxel alone in patients with squamous-cell carcinoma of the esophagus, refractory or intolerant to combination therapy with fluoropyrimidine and platinum-based drugs - RAMOS, a randomized phase II trial of the German Gastric Group of the AIO

Full Text